56 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
in writing, any person of any Personal Data or security-related incident. Neither the Company nor any Subsidiary has received any written notice of any … , the Company hereby agrees to pay all costs and expenses incident to the performance of its obligations hereunder, including the following: (i) all expenses
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
the Company, the Subsidiaries or any of their properties or assets to notify in writing, any person of any Personal Data or security-related incident … , the Company hereby agrees to pay all costs and expenses incident to the performance of its obligations hereunder, including the following: (i) all
8-K
EX-1.2
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
to be performed or satisfied hereunder at or prior to such Closing Date.
(d) All corporate proceedings and other legal matters incident
8-K
EX-10.1
0cvhlb7jkk44zh 0vc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
4s064y27i1k53vd
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
aapnq7rzuzepxf
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-10.1
osf5ylcpml
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
ueb8soe4qn1nspatoy
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
5a7og745
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
atti h6uy72wi86q
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-1.1
h3mq16
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-1.1
1mvq2j3xsq 1zv3me31
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm